Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|17|1|62-73

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.17, Iss.1, 2016-12, pp. : 62-73

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sorafenib in locally advanced or metastatic breast cancer

By Gradishar William J  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 8, 2012-08 ,pp. : 1177-1191

Informa Healthcare

Access to resources Recommend Favorite

Ixabepilone: In Locally Advanced or Metastatic Breast Cancer

By Moen Marit D.  

Drugs, Vol. 69, Iss. 11, 2009-07 ,pp. : 1471-1481

Adis International

Access to resources Recommend Favorite

Tipifarnib, a farnesyl transferase inhibitor, appears to have potential for patients with locally advanced breast cancer

By  

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

The p53 gene therapy Advexin has demonstrated positive results in locally-advanced breast cancer

By  

Inpharma, Vol. 1, Iss. 1468, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Tailoring Therapy for Locally Advanced Breast Cancer Using Molecular Profiles: Are We There Yet?

By Fosker Christopher  

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 1947-1955

Adis International

Access to resources Recommend Favorite